Why AI matters at this scale

INC Research is a large clinical research organization (CRO) that provides biopharmaceutical services to support drug development. With over 10,000 employees, the company operates globally, managing complex clinical trials from design through regulatory submission. Its work is data-intensive, involving patient recruitment, monitoring, safety reporting, and statistical analysis. The pharmaceutical R&D sector faces pressure to reduce development costs and timelines, which often exceed a decade and billions of dollars. AI presents a transformative lever for efficiency and innovation.

For a company of this size in the CRO space, AI adoption is not just a competitive advantage but a strategic necessity. The scale generates vast amounts of structured and unstructured data—from electronic health records and genomic databases to clinical notes and imaging. Leveraging this data with AI can unlock insights that manual processes cannot. Large enterprises like INC Research have the financial resources to invest in AI infrastructure and specialized talent, but they also face the challenge of integrating new technologies into established, regulated workflows. The potential ROI is significant, as even marginal improvements in trial success rates or speed can translate to hundreds of millions in value for clients and the broader healthcare ecosystem.

Concrete AI Opportunities with ROI Framing

1. AI-Driven Patient Recruitment and Matching: Patient recruitment is a major bottleneck, causing delays that cost up to $8 million per day in lost revenue for drug sponsors. By deploying machine learning models on real-world data (e.g., EHRs, claims data), INC Research can predict patient eligibility and proactively identify candidates. This could cut recruitment time by 30%, directly reducing trial costs and accelerating time-to-market for therapies.

2. Intelligent Trial Design and Simulation: Using historical trial data, AI can simulate various protocol designs to optimize endpoints, sample sizes, and inclusion criteria. This reduces the risk of protocol amendments mid-trial, which are costly and time-consuming. A more robust design increases the likelihood of trial success, improving ROI for both the CRO and its pharmaceutical partners.

3. Automated Regulatory Document Generation: Preparing clinical study reports and submission documents is labor-intensive. Generative AI tools can auto-draft sections based on trial data, ensuring consistency and compliance with regulatory standards. This automation can reduce manual effort by 40%, allowing medical writers to focus on higher-value analysis and quality control.

Deployment Risks Specific to Large Enterprises (10K+ Employees)

Deploying AI at this scale involves several risks. First, data silos and legacy systems are common in large, global organizations. Integrating AI solutions across disparate IT environments requires significant upfront investment and can face internal resistance. Second, regulatory and compliance hurdles are paramount in pharmaceuticals. AI models must be validated, explainable, and auditable to meet FDA and EMA standards, slowing deployment. Third, change management across 10,000+ employees demands robust training programs and clear communication to ensure adoption. Finally, data privacy and security concerns are amplified when handling sensitive patient information; breaches could result in severe legal and reputational damage. Mitigating these risks requires a phased approach, starting with pilot projects in less critical areas, investing in data governance, and fostering partnerships with AI vendors experienced in the life sciences sector.